The objective of the study was to investigate the effectiveness and efficacy of the randomized, parallel, and controlled trial of Traditional Chinese Medicine, general acteoside of Rehmanniae leaves, compared with piperazine ferulate in the treatment of primary chronic glomerulonephritis. Rehmanniae leaves and piperazine ferulate can reduce proteinuria and erythrocyturia effectively in the treatment of primary chronic glomerulonephritis. A total of 400 patients diagnosed with primary chronic glomerulonephritis were recruited from outpatient clinics and were randomly assigned to the treatment group (general acteoside of Rehmanniae leaves, two 200mg tablets, bid) or the control group (piperazine ferulate, four 50-mg tablets, bid ). The primary outcome was 24-h urinary protein. Secondary outcome measures included estimated glomerular filtration rate (eGFR), erythrocyturia, and electrolytes. After 8 weeks of treatment, the treatment group and the control group showed a mean reduction in 24-h proteinuria of 34.81% and 37.66%. The 95% CI of difference of the mean reduction in 24-h proteinuria between the two groups was [-11.50%, 5.80%]. No significant differences were found between the two groups in the erythrocyturia reduction. Neither group showed obvious changes between baseline and 8 weeks in eGFR or electrolytes. Adverse events occurred at a similarly low rate in the treatment group (1.5%) and control group (2.5%, P = 0.7238). Both general acteoside of Rehmanniae leaves and piperazine ferulate can reduce proteinuria and erythrocyturia effectively in the treatment of primary chronic glomerulonephritis.
Introduction
Chronic glomerulonephritis is one of the most common causes of end-stage renal disease among chronic kidney disease patients in China (Zhang et al., 2012) . Although many approaches have been investigated, no single recommended treatment is established. Risk factors associated with poorer outcomes include urinary protein, and impaired renal function (Holtkamp et al., 2011) . Proteinuria has proven to be the most important predictor of renal failure, and therapeutic efforts have been focused on its reduction (Wilmer et al., 2003) .
Traditional Chinese Medicine -general acteoside -refers to several substances present in extracts of We designed this study to evaluate the efficacy and safety of an 8-week regimen of general acteoside in
Rehmanniae leaf extract compared with piperazine ferulate in the treatment of chronic glomerulonephritis.
Materials and Methods
The present research was a prospective, randomized, parallel controlled study. Two hundred (200) subjects in each group were required to achieve 80% power at 0.05 significance level.
Four hundred patients were randomly allocated with a ratio of 1:1 to either treatment group (general acteoside of Rehmanniae leaves, two 200mg tablets, bid) or control group (piperazine ferulate, four 50-mg tablets, bid).
Randomisation was carried out using the Proc Plan Procedure in SAS 9.2 (SAS Institute Inc., Cary, NC, USA).
Medical history, demographic characteristics and physical examination of the patients were recorded at baseline.
Follow-up was conducted at 4 and 8 weeks of treatment. At baseline and 8 weeks of treatment, all patients were subjected to a haematology panel and urinalysis, and the following parameters were assessed: renal function, serum alanine aminotransferase (ALT), aspartate transaminase (AST), and electrolytes.
The primary outcome was the percent reduction in proteinuria between baseline and 8 weeks of treatment.
Secondary outcome measures included the following: estimated glomerular filtration rate (eGFR), which was calculated using the simplified modification of diet in renal disease (MDRD) equation; erythrocyturia and electrolytes.
All eligible patients were asked whether they were willing to participate in the trial and informed about the purpose of the trial, the operative procedures, as well as their options and risks. Written informed consent was obtained from all patients participating in the trial.
All analyses were performed by using the software package SAS version 9. 
Results
A total of 450 patients were screened and 400 patients were randomised: 200 patients to the treatment group and 200 patients to control group. A total of 6 patients lost to follow-up, of whom 1 was from the treatment group.
The randomisation and completion of the study are detailed in Figure 1 . The baseline characteristics of the patients are presented in Table 1 . There was no statistically significant difference between the two groups in any characteristics.
Eighty-two patients received renal biopsies. The morphological changes are shown in Table 2 . This study excluded the glomerulonephritis patients with proliferative lesions at renal biopsy treated with glucocorticoids and immunosuppressive agents. Table 3 shows the 24 hour protein results after 8 weeks. The treatment group and the control group showed a mean reduction in 24-h proteinuria of 34.81% and 37.66%. The 95% CI of difference of the mean reduction in 24-h proteinuria between the two groups was (-11.50%, 5.80%), which indicated that there was no statistical difference in the 24 h urine protein reduction between general acteoside of Rehmanniae leaves and piperazine ferulate in the treatment of patients with primary chronic glomerulonephritis.
Screened for eligibility (n=450)
Randomized allocated (n=400)
Treatment group (n=200) Lost to follow up (n= 1)
Analysed using intention to treat (n=200)
Control group (n=200) Lost to follow up (n=5 )
Analysed using intention to treat (n=200) Excluded (n=50) Table 4 shows the improvement of reducing the urinary erythrocyte excretion in both groups. No significant differences were found between the two groups in the erythrocyturia reduction.
Analysis of eGFR variation showed no significant differences in the two groups. There was no statistical difference between the two groups with regard to serum albumin, potassium, calcium and phosphate, see table 5.
Overall, adverse events occurred at a similarly low rate in the treatment group (1.5%) and control group (2.5%, P = 0.7238). The adverse events experienced by patients in both groups were mild and transient. In the treatment group, one (0.5%) patient reported dizziness, one (0.5%) patient,fatigue; and one (0.5%) patient had a cold. In the control group, two (1%) patients reported mild stomach discomfort; one (0.5%) patient, thirsty; one (0.5%) patient, the stool is not forming; and one (0.5%) patient, joint pain. All these symptoms disappeared without treatment. **comparisons between groups; P 1 , comparisons within groups from baseline to week 4 P 2 , comparisons within groups from baseline to week 8; Abbreviations: HP, high power mirror field of vision. **Differences between baseline and 8 weeks of treatment were similar for the two groups (P > 0.05).
Discussion
The pathogenesis of primary chronic glomerulonephritis is still unknown, and proteinuria is one of the most hence, the choice of a selected group of chronic glomerulonephritis patients with mild or moderate histologic lesions and proteinuria, which may limit the applicability of this therapeutic intervention to certain patients.
Therefore, further clinical studies with longer follow-up or with immunosuppressive agents-treated patients are necessary to evaluate the effectiveness of this treatment.
Conclusion
Both general acteoside of Rehmanniae leaves and piperazine ferulate can reduce proteinuria effectively in the treatment of primary chronic glomerulonephritis. Both medicines reduce erythrocyturia. Studies with proliferative nephritis and longer follow-up are necessary to confirm the effectiveness and the benefits of general acteoside of Rehmanniae leaves and piperazine ferulate in clinical practice.
